Establishment and characterization of intraperitoneal xenograft models by co-injection of human tumor cells and extracellular matrix gel

Abstract

Establishing a feasible intraperitoneal (i.p.) xenograft model in nude mice is a good strategy to evaluate the antitumor effect of drugs in vivo. However, the manipulation of human cancer cells in establishing a stable peritoneal carcinomatosis model in nude mice is problematic. In the present study, the ovarian and colorectal peritoneal tumor models were successfully established in nude mice by co-injection of human tumor cells and extracellular matrix gel. In ovarian tumor models, the mean number tumor nodes was significantly higher in the experimental group (intraperitoneal tumor cell co-injection with ECM gel) compared with the PBS control group on the 30th day (21.0±3.0 vs. 3.6±2.5; P<0.05). The same results were observed in the colorectal peritoneal tumor models on the 28th day. The colorectal peritoneal tumor model was further used to evaluate the chemotherapy effect of irinotecan (CPT-11). The mean weight of peritoneal tumor nodes in CPT-11 treatment group was significantly less than that of the control group (0.81±0.16 vs. 2.18±0.21 g; P<0.05). The results confirmed the value of these i.p. xenograft models in nude mice as efficient and feasible tools for preclinical evaluation.

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib

“…Four out of eight mice treated with neratinib (4 normal and 4 cancer treated) exhibited ocular toxicity. Similarly, in the previous studies, one out of nine mice showed atrophy in the corneal epithelium after neratinib treatment (25 mg/kg) ( Davis, 2016 , Yao et al, 2015 ). These symptoms are consistent with the ocular side effects reported for TKIs since HER1 is highly expressed in the eyes ( Chang et al, 2011 , Rajala et al, 2017 ).…”

Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial

“…But considering that the concentration of 100 μM is higher than those considered to cause lidocaine toxicity in plasma [namely 5 μg/ml (15) or approximately 21 μM] an in vitro to in vivo translation experiment was strongly required to connect in vitro observations with clinical application. We chose an intraperitoneal xenograft in nude mice as a preclinical model (43). SCID mice express normal population and function of natural killer, macrophage and granulocyte cells (44) and lidocaine also has indirect antitumor properties by enhancing natural killer cell functions (23) and modulating the tumor microenvironment (25)(26)(27).…”

Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications

“…These mice are unable to generate an immune response against human cells and tumor engraftment is thus promoted in the peritoneal cavity. The xenografted PCa models have been studied using colon cancer (HCT-116, LS174T, HT29, SW480, SW620, LoVo, RKO, Caco-2, KM12, MDST8, HUTU80) [ 57 , 58 , 59 , 60 , 61 ], pancreatic cancer (Panc-1, TCC-Pan2, BxPC3, AsPC-1) [ 62 , 63 , 64 ], gastric cancer (60As6, HSC-44PE, HSC-58, MKN45-P) [ 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ], and ovarian cancer (OVCAR3, OVCAR4, OVCAR5, OVCAR8, CAOV3, OVSAHO, OV2944-HM-1, SKOV-3) [ 59 , 70 , 71 , 72 ] cell lines. These models have been used to attain proofs of concept and explore treatments that determine in vivo tumor cell cytotoxicity of drugs, such as chemotherapeutic agents.…”